<DOC>
	<DOCNO>NCT00026091</DOCNO>
	<brief_summary>Phase II trial study effectiveness fenretinide treat patient recurrent metastatic ovarian epithelial primary peritoneal cancer . Drugs use chemotherapy , fenretinide , work different way stop growth tumor cell , either kill cell stop divide</brief_summary>
	<brief_title>Fenretinide Treating Patients With Recurrent Metastatic Ovarian Epithelial Primary Peritoneal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate efficacy fenretinide ( 4-HPR ) patient recurrent ovarian cancer primary peritoneal carcinoma . II . To assess toxicity agent patient population . III . To evaluate molecular change normal tumor cell induce 4-HPR studying : ( ) analysis ceramide glucosyleceramide level therapy , ( b ) intracellular level 4-HPR 4-MPR , ( c ) determinant apoptosis ( p53 , p21 , bcl-2 , bax terminal deoxynucleotidyl transferase [ TdT ] assay ) baseline tumor specimen , serial serum tumor biopsy specimens available , surrogate in-vitro study . IV . To evaluate pharmacokinetics fenretinide . V. To investigate antiangiogenesis effect fenretinide in-vitro assay use ovarian cancer cell line vascular growth factor ( VEGF , TGFb ) plasma level patient . OUTLINE : Patients receive oral fenretinide twice daily day 1-7 . Treatment repeat every 21 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Patients histologically confirm recurrent metastatic epithelial ovarian cancer primary peritoneal carcinoma Unidimensionally measurable disease ; indicator lesion must irradiate unless grown follow radiation therapy SWOG performance status 02 Patients must receive platinum paclitaxel contain regimen Patients allow receive = &lt; 2 prior chemotherapy regimens recurrent disease ; patient rechallenged chemotherapy regimen consider regimen Projected life expectancy must least 3 month Signed informed consent Absolute neutrophil count &gt; = 1500/ul Platelet count &gt; = 100,000 ul Bilirubin = &lt; 2 time institutional limit normal ALT AST = &lt; 3 time upper limit normal Measured calculate creatinine clearance &gt; = 60 ml/min Fasting triglycerides = &lt; 1 time upper limit normal ; triglyceride may `` normalize '' prior study entry use antilipemic agent ( atorvastatin , fenofibrate ) Patients must recover acute toxicity surgery , radiation chemotherapy ; least 3 week elapse since prior therapy direct malignant tumor Patients childbearing potential must agree use approve method birth control Prior fenretinide allow ; prior 13cis , 9cis alltransretinoic acid allow Patients second malignancy within last 5 year allow , except nonmelanomatous skin cancer carcinomainsitu cervix ; prior invasive malignancy must complete remission The use concomitant antioxidant , vitamin C E , allow Patients concurrent medical , psychological social condition severity investigator deem unwise enter patient protocol Untreated symptomatic brain metastasis Pregnant nursing woman</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>